Related Experiment Video
Updated: Sep 29, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
First trimester serum matrix metalloproteinase-7 is a poor predictor of late-onset preeclampsia
Julie Dahl Ravn1, Emma Julie Bendix1, Lene Sperling2
1Department of Obstetrics and Gynecology, Odense University Hospital, Odense, Denmark.
Objectives:
This study aims to evaluate matrix metalloproteinase-7 as a first trimester biomarker for late-onset preeclampsia, both alone and in combination with mean arterial pressure, uterine artery pulsatility index, and maternal characteristics.
Study Design:
We conducted a nested case-control study from a prospective cohort consisting of 416 pregnant women who attended a routine first trimester scan. Baseline variables were obtained at inclusion and analysed subsequently to formation of case and control groups. The study was designed to detect a mean difference of > 15% in matrix metalloproteinase-7 concentrations between groups with a statistical power of 80%.
Main Outcome Measures:
The primary outcome was preeclampsia with delivery after 34 weeks of pregnancy.
Results:
The median matrix metalloproteinase-7 concentration in cases of late-onset preeclampsia (n = 27) was marginally lower compared to normotensive controls but this difference was not statistically significant. Matrix metalloproteinase-7 predicted 14.8% of cases at a 10% false-positive rate. Addition of matrix metalloproteinase-7 to any combination of variables did not significantly improve their performance.
Conclusions:
Matrix metalloproteinase-7 is not a useful biomarker for late-onset preeclampsia, neither alone nor in combination with mean arterial pressure, uterine artery pulsatility index, or maternal characteristics.
More Related Videos
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
Mitral Valve Prolapse III: Nursing Management

